USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Investment is additive to KKR’s existing health care growth strategy
The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease
Approval of oral, once-daily VELSIPITY based on favorable safety and efficacy data from the ELEVATE UC Phase 3 trials
GenWorks Health Introduces Braster Pro for breast screening & EVA for cervical screening in rural areas & communities
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Subscribe To Our Newsletter & Stay Updated